Bio-Matrix Scientific Group Inc.'s Subsidiary Applies for Phase II Grant from National Cancer Institute for the Development of Immuno-Therapeutic Cancer Vaccine
SAN DIEGO--(BUSINESS WIRE)--Entest BioMedical, Inc. (OTCBB: ENTB) a majority owned subsidiary of Bio-Matrix Scientific Group, Inc. (OTCBB: BMSN) announced today that it has applied for an Exploratory/Development Phase II grant from the National Cancer Institute (NCI).